CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue
Total operating revenue	$ 119,802	$ 98,578	$ 224,208	$ 193,244
Operating expenses
Selling, general and administrative expense	26,907	27,872	52,283	56,324
Depreciation and amortization	1,805	1,518	3,589	3,007
Total operating expenses	131,013	114,942	245,330	227,580
Loss from operations	(11,211)	(16,364)	(21,122)	(34,336)
Other non-operating expense (income)
Interest expense, net	1,870	2,118	7,440	4,103
Change in fair value of derivative warrant liabilities	53	(552)	96	(552)
Change in fair value of conversion option derivative liabilities	3,987	(2,568)	7,296	(2,568)
Other, net	19	117	771	49
Total other non-operating loss (income)	5,929	(885)	15,603	1,032
Loss before provision for income taxes	(17,140)	(15,479)	(36,725)	(35,368)
Income tax benefit (expense)	131	0	131	0
Net loss	(17,009)	(15,479)	(36,594)	(35,368)
Net loss attributable to common stockholders, basic	(13,991)	(12,679)	(30,072)	(28,953)
Net loss attributable to common stockholders, diluted	$ (13,991)	$ (12,679)	$ (30,072)	$ (28,953)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.15)	$ (0.17)	$ (0.35)	$ (0.39)
Diluted (in dollars per share)	$ (0.15)	$ (0.17)	$ (0.35)	$ (0.39)
Weighted-average number of shares outstanding:
Basic (in shares)	93,203,665	74,748,365	85,195,734	74,491,326
Diluted (in shares)	93,203,665	74,748,365	85,195,734	74,491,326
Patient services
Revenue
Total operating revenue	$ 55,891	$ 52,461	$ 108,959	$ 104,914
Operating expenses
Direct costs	51,150	46,522	98,230	96,019
Dispensary
Revenue
Total operating revenue	62,573	44,440	111,866	84,119
Operating expenses
Direct costs	51,086	38,801	90,949	71,610
Clinical trials & other
Revenue
Total operating revenue	1,338	1,677	3,383	4,211
Operating expenses
Direct costs	$ 65	$ 229	$ 279	$ 620